Assessment of Gastrointestinal Dysfunction Through GIDS Scale and Intestinal Damage Biomarkers in Critically Ill Patients Undergoing Aortic Surgery and Its Association With Clinical Outcomes.

The goal of this observational study is to determine the association of gastrointestinal dysfunction through the Gastrointestinal Dysfunction Scale (GIDS) tool and serum concentrations of citrulline and Intestinal fatty-acid binding protein (I-FABP) with primary [calories received, protein received, parenteral nutrition requirement and 28-day mortality in the intensive care unit (ICU)] and secondary (development of pneumonia, surgical and cardiovascular complications in the ICU, length of hospital and ICU stay, duration of mechanical ventilation) clinical outcomes in critically ill patients undergoing aortic surgery.

Start Date23 Jul 2024

Sponsor / Collaborator

Instituto Nacional de Cardiología Ignacio Chávez

[+2]

NCT06064838

/ CompletedNot ApplicableIIT

Effects of Cacao Flavonoids in Long COVID-19 Patients with Chronic Fatigue (FLALOC)

The study use a triple blind, placebo-controlled design enrolling male and female subjects between 30-70 yo to evaluate the effect of daily consumption of a cacao supplement on inflammation, endothelial damage, handgrip strength, fatigue scale and quality of life.

Start Date01 Aug 2023

Sponsor / Collaborator

Instituto Politecnico Nacional

[+1]

NCT05579119

/ CompletedPhase 4IIT

Efficacy and Safety of Sitagliptin and Glargine Compared to a Basal-plus Insulin Regimen in Hospitalized Patients With Type 2 Diabetes

In noncritically hospitalized patients, hyperglycemia (defined as blood glucose [BG] levels >140 mg/dL) is a common, serious, and costly healthcare problem. On the other hand, the treatment of hyperglycemia is associated with decreased mortality and morbidity. Therefore, clinical guidelines from professional organizations recommend using subcutaneous insulin as the preferred therapy in hospitalized patients in a non-intensive care unit setting (target glucose range 100 - 180 mg/dl). The most recommended regimen is basal-bolus insulin therapy, although this regimen requires multiple daily insulin injections and is associated with a significant risk of hypoglycemia (reported in up to 32%). Thus, a more straightforward regimen that results in similar glycemic efficacy to basal-bolus insulin with less risk of hypoglycemia could improve care for this group of patients.
The basal-plus insulin regimen consists of a daily dose of basal insulin with supplemental (corrective) doses of rapid-acting insulin analogue before meals. This has similar efficacy and safety as the basal-bolus regimen. However, the basal-plus scheme does not provide prandial coverage of insulin.
In another vein, dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral glucose-lowering agents that reduce the breakdown of endogenous glucagon-like peptide-1 (GLP-1), stimulating insulin secretion in a glucose-dependent manner. Some clinical trials have demonstrated that DPP-4 inhibitors, in combination with insulin, result in similar improvement in glycemic control and lower rates of hypoglycemia compared to basal-bolus insulin regimens.
For the above, using a long-acting insulin analogue with a DPP-4 inhibitor could provide better glycemic control basal and prandial, and this scheme could represent an alternative to using a basal-plus regimen alone.
In the present study, the investigators will conduct a prospective randomized clinical trial (RCT) to compare the DPP-4 inhibitor, sitagliptin, combined with basal-plus insulin therapy and basal-plus insulin scheme alone in non-critical hospitalized patients.

Start Date06 Jul 2022

Sponsor / Collaborator

Instituto Mexicano del Seguro Social

[+1]

100 Clinical Results associated with Instituto Politecnico Nacional

0 Patents (Medical) associated with Instituto Politecnico Nacional

78,567

Literatures (Medical) associated with Instituto Politecnico Nacional

31 Dec 2025·Journal of Enzyme Inhibition and Medicinal Chemistry

Myeloperoxidase as a therapeutic target for oxidative damage in Alzheimer’s disease

Review

Author: Torres-Ramos, Mónica A. ; Rosales-Hernández, Martha Cecilia ; Rivera Antonio, Astrid Mayleth ; Padilla Martínez, Itzia Irene

Alzheimer's disease (AD) is a major neurodegenerative disorder more common in older adults. One of the leading AD hypotheses involves the amyloid beta (A) production, it is associated to oxidative stress, neuroinflammation, and neurovascular damage. The interaction of A with the blood vessel wall contributes to the disruption of the blood-brain barrier (BBB), allowing neutrophil infiltration containing the myeloperoxidase enzyme (MPO), which produces hypochlorous acid (HOCl) a potent oxidant. Also, MPO could be released from the microglia cells and interact with the amyloid beta plaques. This review aims to study the role of MPO in the progression of AD, in particular its contribution to oxidative stress and neuroinflammation. Furthermore, to explore the MPO-potential as AD-biomarker to evaluate the therapeutic potential of its inhibitors to mitigate the neurotoxicity. Finally, revise MPO inhibitors that could act as dual inhibitors acting on MPO and acetylcholinesterase and or another target involved in AD.

01 Dec 2025·Immunogenetics

Uncovering selection pressures on the IRF gene family in bats’ immune system

Article

Author: Ortega, Jorge ; Gutierrez, Edgar G

Unlike other mammals, bats serve as natural reservoirs for several highly pathogenic viruses without exhibiting symptoms of infection. Recent research has explored the complex mechanisms underlying the balance between bats' antiviral defenses and their pathological responses. However, the evolution of the molecular drivers behind bats' antiviral strategies remains largely unknown. Interferon regulatory factors (IRFs) are essential transcription factors that bind to DNA and regulate the expression of numerous genes involved in antiviral defense, inflammation, immune cell differentiation, apoptosis, and oncogenesis. Our research focused on members of the IRF family, using 17 bat species and four terrestrial mammals available in GenBank. We employed CodeML to detect signs of positive selection through three different models. Statistically significant results were obtained for the IRF-1, IRF-4, IRF-5, IRF-6, and IRF-9 genes, which are known to play pivotal roles in various regulation mechanisms. Specifically, IRF-4 and IRF-5 are key in modulating the inflammatory response, while IRF-1 is essential for antiviral defense in bats, and IRF-9 regulates genes activated by type I interferon. Although the role of IRF-6 in these mechanisms requires further investigation in bats, all these genes show signs of positive selection, suggesting an optimization of the processes they regulate. These findings highlight the adaptive role of IRF elements in enhancing, among other things, the bat immune system, potentially improving their resilience and efficacy. Our study not only provides new genetic insights into bats but also underscores the remarkable molecular evolution within this unique group of mammals.

01 Jul 2025·Archives of Medical Research

Extraosseous Plasmacytoma Confers Poor Outcomes in Primary Plasma Cell Leukemia

Article

Author: Sanchez-Rodriguez, Ana Sofia ; Vela-Ojeda, Jorge ; Ramirez-Alvarado, Aline ; Montiel-Cervantes, Laura Arcelia ; Garcia-Chavez, Jaime

BACKGROUNDPrimary plasma cell leukemia (PPCL) is one of the most aggressive diseases in oncohematology. Due to its low incidence, there is no established standard treatment, and it is considered an incurable disease.AIMSThis study presents our experience and outcomes of 92 cases of PPCL between January 2011 and December 2020.METHODSFat pad biopsy was positive for Congo red in six (35 %) of 17 patients, solitary extraosseous plasmacytoma was observed in 30 (32.5 %), and bone marrow fibrosis was identified in 81 (88 %) patients.RESULTSWhile most patients (69.5 %) received conventional chemotherapy combinations, 30.5 % underwent proteasome inhibitor-based treatment and/or autologous stem cell transplantation (auto-SCT). In this series, we report that the presence of extraosseous plasmacytoma, treatment failure, and therapy with classic chemotherapy agents were independent covariates associated with poor survival.CONCLUSIONSIn PPCL, extraosseous plasmacytoma, treatment failure, and treatment with conventional chemotherapy were associated with poor outcomes.

News (Medical) associated with Instituto Politecnico Nacional

24 Oct 2023

·www.prnewswire.com

Pew Funds 6 Teams to Advance Cutting-Edge Biomedical Research

PHILADELPHIA, Oct. 24, 2023 /PRNewswire/ -- The Pew Charitable Trusts announced today the six pairs of researchers who will make up its 2023 class of Innovation Fund investigators. These 12 acclaimed scientists—all alumni or advisors of Pew's biomedical programs in the United States and Latin America—will partner on interdisciplinary research projects exploring key questions in human biology and disease. Combining the researchers' expertise in topics ranging from neuroscience and immunology to cancer biology, these collaborations will help boost scientific discovery and improve human health. Continue Reading The Pew Charitable Trusts announced today the six pairs of researchers who will make up its 2023 class of Innovation Fund investigators. Post this "An interdisciplinary approach to research is critical to uncovering scientific breakthroughs and making lasting change," said Donna Frisby-Greenwood, senior vice president for Philadelphia and scientific advancement at The Pew Charitable Trusts. "Pew is thrilled to support this exceptional group of investigators, whose collective efforts will help move the needle in important areas of health and medicine." For nearly 40 years, Pew has encouraged collaboration among its diverse community of biomedical scientists, leading to the 2017 launch of the Innovation Fund. The award, which is supported by the Kathryn W. Davis Peace by Pieces Fund, was developed to support creative and cross-disciplinary partnerships among alumni of Pew's three biomedical programs. Program alums holding assistant professor positions or higher are eligible to apply. This year's Innovation Fund teams and research projects are: Katsuhiko Murakami, Ph.D., 2005 Pew biomedical scholar; Pennsylvania State University Gene-Wei Li, Ph.D., 2017 Pew biomedical scholar; Massachusetts Institute of Technology Murakami and Li will study transcription termination, a critical step of gene regulation in a distinct group of bacteria known as cyanobacteria, which play a key role in carbon fixation and cause illness in humans and livestock. Donita C. Brady, Ph.D., 2016 Pew biomedical scholar; University of Pennsylvania Perelman School of Medicine Kivanç Birsoy, Ph.D., 2018 Pew-Stewart scholar; The Rockefeller University Brady and Birsoy will team up to identify cell components that regulate—or respond to—transition metals, key dietary nutrients that maintain health in humans and other organisms. Roozbeh Kiani, M.D., Ph.D., 2016 Pew biomedical scholar; New York University Nuo Li, Ph.D., 2018 Pew biomedical scholar; Baylor College of Medicine Kiani and Li will explore what happens in the brain when we change our minds, a poorly understood aspect of decision-making. Jesse H. Goldberg, M.D., Ph.D., 2014 Pew biomedical scholar; Cornell University Robert C. Froemke, Ph.D., 2012 Pew biomedical scholar; New York University Grossman School of Medicine Goldberg and Froemke will examine the unique vocalizations of songbirds and mice to better understand the ways in which animals respond to their young's need to feed. Patricia Leon Mejia, Ph.D., 1992 Pew Latin American fellow; Universidad Nacional Autónoma de México Luis G. Brieba de Castro, Ph.D., 2002 Pew Latin American fellow; Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional Leon Mejia and Brieba de Castro will investigate how the plastid, a key organelle in plants, is responsible for metabolism and nutrient production and communicates with the cell's nucleus to respond to external stressors—work that could improve crop yield. Dan R. Littman, M.D., Ph.D., Pew Biomedical Scholars advisor; New York University Grossman School of Medicine Michael Birnbaum, Ph.D., 2018 Pew-Stewart scholar; Massachusetts Institute of Technology Littman and Birnbaum will study the pathology of the microbes and T cells that play a role in inflammatory bowel disease, an autoimmune disorder whose cause is largely unknown. Celebrating its 75th anniversary, The Pew Charitable Trusts uses data to make a difference. Pew addresses the challenges of a changing world by illuminating issues, creating common ground, and advancing ambitious projects that lead to tangible progress. MEDIA CONTACT Erin Davis Manager, Communications 202-540-6677 SOURCE THE PEW CHARITABLE TRUSTS

100 Deals associated with Instituto Politecnico Nacional

100 Translational Medicine associated with Instituto Politecnico Nacional

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 03 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CYP51 inhibitors-4f(Instituto Politécnico Nacional) ( CYP51 (Yeast) )	Mycoses More	Preclinical
CYP51 inhibitors-4h(Instituto Politécnico Nacional) ( CYP51 (Yeast) )	Mycoses More	Preclinical
CYP51 inhibitors-6b(Instituto Politécnico Nacional) ( CYP51 (Yeast) )	Mycoses More	Preclinical
CYP51 inhibitors-6h(Instituto Politécnico Nacional) ( CYP51 (Yeast) )	Mycoses More	Preclinical
CYP51 inhibitors-6j(Instituto Politécnico Nacional) ( CYP51 (Yeast) )	Mycoses More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis